Kiraz, AslıhanSezer, ÖzlemAlemdar, AdemCanbek, SezinDuman, NilgünBişgin, AtılCora, TülinRuhi, Hatice IlgınErgören, Mahmut ÇerkezGeçkinli, Bilgen BilgeSağ, Şebnem ÖzemriGözden, Hilmi ErdemÖz, ÖzlemAltıntaş, Zühal MertYalçıntepe, SinemKeskin, AdemTak, Ayşegüel YabacıPaskal, Şeyma AktaşYürekli, Uğur FahriDemirtaş, MercanEvren, Emine ÜnalHanta, AbdullahBaşdemirci, MüeşerrefSüer, KayaBalta, BurhanKocak, NadirKarabulut, Halil GuerhanÇobanoğulları, HavvaAteş, Esra ArslanBozdoğan, Sevcan TuğEker, DamlaEkinci, SadiyeNergiz, SueleymanTuncali, TimurYagbasan, SerapAlavanda, CerenKutlay, Nuket YururEvren, HakanErdogan, MuratAltiner, SuleSanlidag, TamerGonen, Gizem AkinciVicdan, ArzuEras, NazanEker, Hatice KocakBalasar, ÖzgürTuncel, GultenDündar, MunisGürkan, Hakan2024-07-012024-07-012023-02-010146-6615https://doi.org/10.1002/jmv.28457https://onlinelibrary.wiley.com/doi/10.1002/jmv.28457https://hdl.handle.net/11452/42662Thrombotic and microangiopathic effects have been reported in COVID-19 patients. This study examined the contribution of the hereditary thrombophilia factors Prothrombin (FII) and Factor V Leiden (FVL) genotypes to the severity of COVID-19 disease and the development of thrombosis. This study investigated FII and FVL alleles in a cohort of 9508 patients (2606 male and 6902 female) with thrombophilia. It was observed that 930 of these patients had been infected by SARS-CoV-2 causing COVID-19. The demographic characteristics of the patients and their COVID-19 medical history were recorded. Detailed clinical manifestations were analyzed in a group of cases (n = 4092). This subgroup was age and gender-matched. FII and FVL frequency data of healthy populations without thrombophilia risk were obtained from Bursa Uludag University Medical Genetic Department's Exome Databank. The ratio of males (31.08%; 27.01%) and the mean age (36.85 & PLUSMN; 15.20; 33.89 & PLUSMN; 14.14) were higher among COVID-19 patients compared to non-COVID-19 patients. The prevalence of FVL and computerized tomography (CT) positivity in COVID-19 patients was statistically significant in the thrombotic subgroup (p < 0.05). FVL prevalence, CT positivity rate, history of thrombosis, and pulmonary thromboembolism complication were found to be higher in deceased COVID-19 patients (p < 0.05). Disease severity was mainly affected by FVL and not related to genotypes at the Prothrombin mutations. Overall, disease severity and development of thrombosis in COVID-19 are mainly affected by the variation within the FVL gene. Possible FVL mutation should be investigated in COVID-19 patients and appropriate treatment should be started earlier in FVL-positive patients.eninfo:eu-repo/semantics/openAccessSars-cov-2 infectionFrequencyPopulationG20210aCovid-19Factor v leidenProthrombinThrombophiliaVirologyArticle00103494930012895210.1002/jmv.28457